Blockchain Registration Transaction Record

LakeShore Biopharma Goes Private in Amended Merger Deal

LakeShore Biopharma enters amended merger agreement to go private at US$0.066 per share, implying US$2.7M equity value. Transaction led by Oceanpine Skyline Inc. and Rollover Shareholders.

This news matters because it involves a significant reduction in the valuation of LakeShore Biopharma, a biopharmaceutical company with a promising PIKA® platform for vaccines. Shareholders face a drastically lower payout from US$0.90 to US$0.066 per share, highlighting the risks of investing in small-cap biotech stocks. The going-private transaction may affect the company's future transparency and access to capital, but it could allow management to focus on long-term research without quarterly earnings pressure.